

FILE COPY

Created by MATTHEW M. SEN

Page 1 of 2

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

INNS:008-3

To be assigned

List of Patents and Publications for Applicant's

Applicant

INFORMATION DISCLOSURE STATEMENT

Lieven Stuyver, Joost Louwagie, and Rudi Rossau

(Use several sheets if necessary)

Filing Date:

Group:

Filed herewith

To be assigned

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1-2



### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,409,810	04/25/95	Larder et al.	435	5	12/01/92
	A2	5,631,128	05/20/97	Kozal et al.	435	5	08/15/94
	A3	5,759,770	06/02/98	Guertler et al.	435	5	06/06/95
	A4	5,827,648	10/27/98	Eastman et al.	435	5	07/29/96

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO92/16180 A	10/01/92	WIPO			
	B2	0 422 762 A	04/17/91	EPO			
	B3	WO94/12670 A	06/09/94	WIPO			
	B4	0 532 258 A	03/17/93	EPO			

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Mellors et al., "Mutations in HIV-1 Reverse Transcriptase and Protease Associated with Drug Resistance," <i>Int. Antiviral News</i> 3:8-13 (1995)
	C2	Schinazzi et al., "Mutations in HIV-1 Reverse Transcriptase and Protease Associated with Drug Resistance," <i>Int. Antiviral News</i> 2:72-74 (1994)
	C3	Larder et al., "Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)," <i>Science</i> 246:1155-1158 (1989)
	C4	Eron et al., "Susceptibility Testing by Polymerase Chain Reaction DNA Quantitation: A Method to Measure Drug Resistance of Human Immunodeficiency Virus Type 1 Isolates," <i>Proceedings of the National Academy of Sciences of USA</i> 89:3241-3245 (1992)

EXAMINER:

HORLICK

DATE CONSIDERED:

3/13/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. INNS:008--3	Serial No. To be assigned
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Lieven Stuyver, Joost Louwagie, and Rudi Rossau	
		Filing Date: Filed herewith	Group: To be assigned
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-2</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>MM</i>	C5	Gingeras et al., "Use of Self-Sustained Sequence Replication Amplification Reaction to Analyze and Detect Mutations in Zidovudine-Resistant Human Immunodeficiency Virus," <i>The Journal of Infectious Diseases</i> 164:1066-1074 (1991)
	C6	Stuyver et al., "Typing of HCV Isolates and Characterisation of New Subtypes Using a Line Probe Assay," <i>J. Gen. Virol.</i> 74:1093-1102 (1993)
	C7	Lipshutz et al., "Using Oligonucleotide Probe Arrays to Access Genetic Diversity," <i>Biotechniques</i> 19:442-447 (1995)
	C8	Iversen et al., "Multidrug Resistant HIV-1 Strains Resulting from Combination Antiretroviral Therapy," <i>J. Virol.</i> 70:1086-1090 (1996)
	C9	Stuyver et al., "Line Probe Assay for Rapid Detection of Drug-Selected Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene," <i>Antimicrobial Agents and Chemotherapy</i> 41:284-291 (1997).
<i>MM</i>	C10	Shafer et al., "Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy", <i>J. Inf. Diseases</i> , 172:70-78 (1995)

EXAMINER: HURLICKDATE CONSIDERED: 3/13/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)